Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

← catalyst calendar

NCT05329194 · results posted

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.

Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
286actual
Sites
37
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-04-29actualWhen the study began enrolling
Primary completion2025-10-01actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-10-01actualThe whole study's end, after follow-up
First posted2022-04-14actualWhen this record first appeared on the registry
Results posted2026-07-16actualWhen the sponsor posted results to the registry
Record updated2026-07-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Asthma

Intervention

  • Drug: Tezepelumab — also filed as AMG 157 or MEDI9929

Primary outcome

what the primary-completion date above is the date OF
Annualized Asthma Exacerbation Rate (AAER)
measured Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-01-12 · 5.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-11 · 1.9 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed